ArticleCHEST pulmonary2025
Detection of SARS-CoV-2 RNA and Biomarkers in Device-Captured Droplets From the Lung.
Article in CHEST pulmonary, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: SARS-CoV-2 remains a global health issue since its discovery in 2019, and long-term noninvasive clinical testing methods are required. The current preferred method of detection is nasopharyngeal swab, which reflects sampling of the upper respiratory tract alone. Research Question: Can we noninvasively assess detection of SARS-CoV-2 RNA and biomarkers in patients' cough droplets captured with the PneumoniaCheck device? Study Design and Methods: We enrolled adult patients with a recent nasopharyngeal swab that was positive for COVID-19 by polymerase chain reaction (PCR) who were receiving monoclonal antibody infusion therapy. After consent and instruction, patients coughed 5 sets of 10 coughs into the PneumoniaCheck device. Material captured on the device filter was eluted and tested for biomarkers (interferon gamma, tumor necrosis factor alpha [TNF-α], IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, and IL-13) and amylase by an enzyme activity assay, and SARS-CoV-2 RNA by PCR (3 different primer sets). Results: A total of 44 case patients out of 50 cases and 17 control patients with adequate specimen and accompanying clinical data were included in the analysis. Thirty case patient cough specimens (68%) tested PCR positive for SARS-CoV-2 RNA, 10 (23%) tested negative, and 4 (9%) tested indeterminate. IL-13 and TNF-α levels were significantly higher, whereas IL-2 levels were significantly lower in case specimens than in control cough specimens. In the multivariable analysis of biomarkers and reported symptoms, higher IL-10 levels were associated with reduced fatigue (OR, 0.41; 95% CI, 0.15-0.87; Interpretation: Our results show that the PneumoniaCheck device is a noninvasive method for successfully detecting SARS-CoV-2 and inflammatory cytokines in specimens from the lower respiratory tract in patients with COVID-19 and likely in patients with other lung diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.